for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
A new world is possible.
Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Vodafone also slips after worries raised over dividend
Mike Coupe needs to stress how competitive and unprofitable supermarkets can be
Generic drugmaker has benefited from popular new products and rival Pfizer’s outage
Pharma group’s interim results show a resilient business
Drugmakers in spotlight over whether they are doing enough to maintain supplies
Generic drugmaker takes $1bn writedown on US business West-Ward Columbus
Anglo American and other miners boosted as Goldman Sachs turns positive on the sector
Leadership change follows series of snags
Pfizer among those risking backlash with new year increases on many medicines
UK stocks drift lower from record high amid thin pre-holiday trading
Injectables and branded medicines offer a tonic for problems with generics
Provident Financial extends rebound after midweek slide
Patients in the US need not choose between fair prices and innovation
Increases mark latest incidence of pharma ‘gouging’
Barcelona attack and US policy paralysis drag UK wider market sharply lower
Group looks to be in danger of losing ground in race to replace asthma treatment
Pharma group warns of sales at lower end of forecasts after Advair blow
Warning follows FDA decision to block generic version of GSK asthma drug